Novacyt S.A. Expansion of PathFlow COVID-19 LFT portfolio (4008D)
June 29 2021 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 4008D
Novacyt S.A.
29 June 2021
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Expansion of PathFlow(R) COVID-19
lateral flow test portfolio
Paris, France and Camberley, UK - 29 June 2021 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, is to launch two PathFlow(R) COVID-19 antigen
lateral flow tests (LFTs) to strengthen the Company's COVID-19
portfolio and to pursue significant new market opportunities,
especially in point-of-care (POC) settings. The Company will
initially target private market opportunities for these LFTs via
its existing distribution network.
Novacyt's two new PathFlow(R) COVID-19 antigen tests are small,
instrument-free and contain all the components required for safe
sample collection, preparation, testing, interpretation of results,
and disposal for convenient use by healthcare professionals or
patients in home settings. The use of point-of-care testing is a
first line rapid screening option and, therefore, Novacyt's
PathFlow(R) antigen LFTs complement the Company's existing
polymerase chain reaction (PCR) portfolio for SARS-CoV-2
diagnosis.
PathFlow(R) COVID-19 Rapid Antigen Pro is a CE Marked LFT for
professional use detecting SARS-CoV-2 antigens using either
anterior nasal samples or nasopharyngeal samples to provide results
in approximately 15 minutes. When using nasal swab specimens, the
test demonstrated a sensitivity of 93.5% and specificity of 99.3%
and when using nasopharyngeal swab specimens, it demonstrated
sensitivity of 93.4% and specificity of 99.4%. Both sampling
methods were tested against 316 samples. This product is available
immediately.
PathFlow(R) COVID-19 Rapid Antigen is a self-test LFT to detect
SARS-CoV-2 antigens using oral fluid samples and provides results
in approximately 15 minutes. This test demonstrated a sensitivity
of 90.1% and specificity of 99.3% from 303 clinical samples. The
test offers mass screening for home, travel, events, and workplace
markets. Novacyt expects to make this LFT available as a CE Marked
product shortly.
PathFlow(R) COVID-19 Rapid Antigen Pro and PathFlow(R) COVID-19
Rapid Antigen have been developed with a partner through an OEM
agreement in conjunction with Novacyt's Microgen Bioproducts
division.
Graham Mullis, Chief Executive Officer of Novacyt,
commented:
"Throughout the pandemic we have continued to launch new
products to ensure our COVID-19 portfolio remains at the forefront
of our industry. These two antigen LFTs will support our customers
as the market continues to evolve towards private testing and we
believe they will become a useful entry point to our existing range
of PCR COVID-19 tests. With the potential for a flu season starting
in the northern hemisphere in a few months it will be important to
know whether a person has flu or SARS-CoV-2 and having access to
quick results are critical to patient treatment and containing the
spread of the COVID-19 virus. These LFTs add to our existing
PathFlow(R) range, which is a portfolio for the rapid diagnosis of
a number of infectious diseases, and we will continue to evaluate
other COVID-19 POC tests to meet the changing demands of the
market."
End
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDDGDLRUDDGBI
(END) Dow Jones Newswires
June 29, 2021 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024